AI Buyer Insights:

● Michelin, an e2open customer evaluated Oracle Transportation Management

● Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

● Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

● Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

● Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

● Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

● Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

● Michelin, an e2open customer evaluated Oracle Transportation Management

● Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

● Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

● Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

● Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

● Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

● Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Omass Therapeutics Tech Stack and Enterprise Applications

IT Decision Makers and Key Stakeholders at Omass Therapeutics

First Name Last Name Title Function Department Email Phone
No data found

Apps Being Evaluated by Omass Therapeutics Executives

APPS RUN THE WORLD tracks software evaluation trends across 2 million companies worldwide, including buyer insights from Omass Therapeutics IT executives and key decision makers. This section highlights Omass Therapeutics's latest recorded technology evaluations, including Zellis MyView for Employee Self Service on 2026-09-09. As part of ARTW Buyer Intent and technographics insights, these findings provide useful visibility into the Omass Therapeutics digital transformation priorities and AI adoption trends.
Date Company Status Vendor Product Category Market
2026-09-09 Omass Therapeutics Evaluated Zellis Zellis MyView Employee Self Service HCM
FAQ - APPS RUN THE WORLD Omass Therapeutics Technographics
Omass Therapeutics is a Life Sciences organization based in United Kingdom, with around 55 employees and annual revenues of $5.0 million.
APPS RUN THE WORLD maintains an up-to-date database of Omass Therapeutics’s key decision makers and IT executives, available to Premium subscribers.
Our research team continuously updates Omass Therapeutics’s profile with verified software purchases, vendor relationships, and digital initiatives identified from public and proprietary sources.
Subscribe to APPS RUN THE WORLD to access the complete Omass Therapeutics technographics profile, including detailed breakdowns by category, vendor, and IT decision makers.